Literature DB >> 26823861

CD40 -1C>T polymorphism and the risk of lung cancer in a Chinese population.

Gang Zhou1, Ying Wang2, Ziyao Fang1, Rongrong Liu1, Anhui Wang3, Feng Zhao4, Lihua Chen1.   

Abstract

BACKGROUND: The co-stimulatory molecule CD40 plays an important role in anti-tumor responses by promoting cytotoxic T lymphocyte (CTL) activity and differentiation of helper T cells. Growing evidence suggests that single nucleotide polymorphisms (SNPs) in CD40 are associated with the susceptibility to cancer. This study investigated the association between the CD40 -1C/T SNP (rs1883832) and lung cancer in a Chinese population.
METHODS: We conducted a hospital-based case-control study including 105 lung cancer patients and 109 healthy control subjects. The -1C/T SNP in CD40 was genotyped by the polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP), and its association with lung cancer susceptibility was evaluated.
RESULTS: The distribution of the genotypes of CD40-1C/T was significantly different between lung cancer patients and controls. The frequency of the TT genotype (adjusted P = 0.017; overall risk [OR] = 2.94; 95% confidence interval [CI] = 1.21-7.13) and TT/CT genotype (adjusted P = 0.020; OR = 1.95; 95% CI = 1.11-3.43) were significantly higher in lung cancer patients than that in controls. When the cases were categorized by tumor histology, the TT genotype was associated with a significantly increased risk of squamous cell carcinoma (adjusted OR = 6.53; 95% CI = 1.97-21.61; P = 0.002).
CONCLUSION: Our findings suggest that the CD40 -1C/T SNP (rs1883832) is correlated with the susceptibility to lung cancer in Chinese, and the TT genotype may further increase the risk of lung cancer.

Entities:  

Keywords:  CD40; lung cancer; single nucleotide polymorphism

Mesh:

Substances:

Year:  2015        PMID: 26823861      PMCID: PMC4713647     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  21 in total

1.  Association analysis of CD40 polymorphisms with asthma and the level of serum total IgE.

Authors:  Ju Hyun Park; Hun Soo Chang; Choon-Sik Park; An-Soo Jang; Byung Lae Park; Tai Youn Rhim; Soo-Taek Uh; Yong Hoon Kim; Il Yup Chung; Hyung Doo Shin
Journal:  Am J Respir Crit Care Med       Date:  2007-01-25       Impact factor: 21.405

2.  A CD40 Kozak sequence polymorphism and susceptibility to antibody-mediated autoimmune conditions: the role of CD40 tissue-specific expression.

Authors:  E M Jacobson; A K Huber; N Akeno; M Sivak; C W Li; E Concepcion; K Ho; Y Tomer
Journal:  Genes Immun       Date:  2007-03-08       Impact factor: 2.676

3.  Association of CD40--1C/T polymorphism with cerebral infarction susceptibility and its effect on sCD40L in Chinese population.

Authors:  Bikui Zhang; Tian Wu; Cuizhu Song; Min Chen; Huande Li; Ren Guo
Journal:  Int Immunopharmacol       Date:  2013-05-10       Impact factor: 4.932

4.  Apoptosis-Related Single Nucleotide Polymorphisms and the Risk of Non-Small Cell Lung Cancer in Women.

Authors:  Anand Pathak; Angela S Wenzlaff; Paula L Hyland; Michele L Cote; Greg R Keele; Susan Land; Matthew L Boulton; Ann G Schwartz
Journal:  J Cancer Ther Res       Date:  2014

5.  Anti-VEGF antibody enhances the antitumor effect of CD40.

Authors:  Sathishkumar Selvaraj; Mahesh Raundhal; Ashok Patidar; Bhaskar Saha
Journal:  Int J Cancer       Date:  2014-03-14       Impact factor: 7.396

6.  Annual report on status of cancer in China, 2010.

Authors:  Wanqing Chen; Rongshou Zheng; Siwei Zhang; Ping Zhao; Hongmei Zeng; Xiaonong Zou; Jie He
Journal:  Chin J Cancer Res       Date:  2014-02       Impact factor: 5.087

7.  A functional TNFRSF5 gene variant is associated with risk of lymphoma.

Authors:  Christine F Skibola; Alexandra Nieters; Paige M Bracci; John D Curry; Luz Agana; Danica R Skibola; Alan Hubbard; Nikolaus Becker; Martyn T Smith; Elizabeth A Holly
Journal:  Blood       Date:  2008-02-20       Impact factor: 22.113

Review 8.  The Janus faces of CD40 in cancer.

Authors:  Angelica S I Loskog; Aristides G Eliopoulos
Journal:  Semin Immunol       Date:  2009-07-31       Impact factor: 11.130

9.  Association of CD40 gene polymorphisms with sporadic breast cancer in Chinese Han women of Northeast China.

Authors:  Chen Shuang; Li Dalin; Yuan Weiguang; Fu Zhenkun; Xu Fengyan; Pang Da; Dianjun Li
Journal:  PLoS One       Date:  2011-08-30       Impact factor: 3.240

10.  Common variants at CD40 and other loci confer risk of rheumatoid arthritis.

Authors:  Soumya Raychaudhuri; Elaine F Remmers; Annette T Lee; Rachel Hackett; Candace Guiducci; Noël P Burtt; Lauren Gianniny; Benjamin D Korman; Leonid Padyukov; Fina A S Kurreeman; Monica Chang; Joseph J Catanese; Bo Ding; Sandra Wong; Annette H M van der Helm-van Mil; Benjamin M Neale; Jonathan Coblyn; Jing Cui; Paul P Tak; Gert Jan Wolbink; J Bart A Crusius; Irene E van der Horst-Bruinsma; Lindsey A Criswell; Christopher I Amos; Michael F Seldin; Daniel L Kastner; Kristin G Ardlie; Lars Alfredsson; Karen H Costenbader; David Altshuler; Tom W J Huizinga; Nancy A Shadick; Michael E Weinblatt; Niek de Vries; Jane Worthington; Mark Seielstad; Rene E M Toes; Elizabeth W Karlson; Ann B Begovich; Lars Klareskog; Peter K Gregersen; Mark J Daly; Robert M Plenge
Journal:  Nat Genet       Date:  2008-09-14       Impact factor: 38.330

View more
  2 in total

1.  Letter to the editor: "The association of CD40 polymorphism (rs1883832C/T) and soluble CD40 with the risk of systemic lupus erythematosus among Egyptian patients".

Authors:  Ilce V Román-Fernández; José F Muñoz-Valle; Claudia A Palafox-Sánchez
Journal:  Clin Rheumatol       Date:  2019-03-07       Impact factor: 2.980

2.  Genetic Variations of CD40 and LTβR Genes Are Associated With Increased Susceptibility and Clinical Outcome of Non-Small-Cell Carcinoma Patients.

Authors:  Foteinos-Ioannis D Dimitrakopoulos; Anna G Antonacopoulou; Anastasia E Kottorou; Melpomeni Kalofonou; Nikolaos Panagopoulos; Dimitrios Dougenis; Thomas Makatsoris; Vasiliki Tzelepi; Angelos Koutras; Haralabos P Kalofonos
Journal:  Front Oncol       Date:  2021-09-17       Impact factor: 6.244

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.